Quarterly ResultJul 23, 2026, 07:02 AM
NovoCure Q2 Net Revenues $184M, +16% YoY; Raises Full-Year Guidance
AI Summary
NovoCure reported record second quarter 2026 financial results, with net revenues increasing 16% year-over-year to $183.6 million, driven by 18% global active patient growth. The company achieved an Adjusted EBITDA of $10.8 million and reduced its net loss to $15.7 million. Key operational achievements include receiving CE Mark for Optune Pax for pancreatic cancer, with Germany being the first EU market for launch. Consequently, NovoCure raised its full-year 2026 net revenue guidance to $710 million - $725 million and Adjusted EBITDA guidance to $0 million - $15 million.
Key Highlights
- Q2 2026 net revenues reached $183.6 million, a 16% increase year-over-year.
- Reported a net loss of $15.7 million for the second quarter.
- Achieved Adjusted EBITDA of $10.8 million for the quarter.
- Total active patients on TTFields therapy globally reached 5,128 as of June 30, 2026.
- Received CE Mark for Optune Pax for locally advanced pancreatic cancer.
- Raised full-year 2026 net revenue guidance to $710 million - $725 million.
- Raised full-year 2026 Adjusted EBITDA guidance to $0 million - $15 million.
- Gross margin for Q2 was 78%, up from 74% in the prior year.
Price Impact
More from NVCR